Pre-made Enoblituzumab benchmark antibody ( Whole mAb, anti-CD276 therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Enoblituzumab biosimilar, Whole mAb, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-184-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Enoblituzumab biosimilar, Whole mAb, Anti-CD276 Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2 therapeutic antibody
INN Name	Enoblituzumab
Target	CD276
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2017
Companies	MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions Approved	na
Conditions Active	Prostate cancer;Solid tumours;Head and neck cancer
Conditions Discontinued	Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer
Development Tech	na